Previous 10 | Next 10 |
2023-09-06 07:33:44 ET More on VBI Vaccines VBI Vaccines slides on discounted stock and warrants offering VBI Vaccines down 3% after hours on public offering VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook For further details see: ...
2023-08-14 09:01:49 ET VBI Vaccines press release ( NASDAQ: VBIV ): Q2 GAAP EPS of -$5.05 misses by $2.89 . Revenue of $0.74M (+111.4% Y/Y) misses by $0.19M . For further details see: VBI Vaccines GAAP EPS of -$5.05 misses by $2.89, revenue of $0.74M miss...
PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 48% quarter-over-quarter from Q1 to Q2 2023 - redefined, highly targeted commercial field team deployed at the end of Q2 Expanded hepatitis B collaboration with Brii Biosciences announced in July for $15 million upfro...
VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the underwriters of its recent underwritten public offering of common shares and accompanying common warrant...
PreHevbri ® is the only approved 3-antigen hepatitis B vaccine for adults in the Netherlands and Belgium Product to be launched via marketing and distribution partner, Valneva VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pu...
2023-07-07 08:29:03 ET Prestige Wealth ( PWM ) +106% . Gorilla Technology Group ( GRRR ) +74% Signs Contract to Deploy Massive Smart Government Project in Egypt. NuZee ( NUZE ) +51% Secures Five-Year Global Licensing Deal with Stone Brewing to...
2023-07-06 13:08:25 ET Gainers: EdtechX Holdings Acquisition ( EDTX ) +40% . Mullen Automotive ( MULN ) +35% . Genius Sports Limited ( GENI ) +21% . Incannex Healthcare Limited ( IXHL ) +19% . Sweetgreen ( SG ) +18% . urban-g...
2023-07-06 09:59:32 ET Shares of VBI Vaccines ( NASDAQ: VBIV ) tumbled 51.7% to $1.17 on Thursday after pricing its underwritten public offering and concurrent registered direct offering to cumulatively raise $21 million. The company priced the public offering of 10,...
Approximately $21 million in gross proceeds from underwritten public offering and concurrent registered direct offering add to upfront payment from Brii Biosciences for a combined $33 million to be received by VBI VBI Vaccines Inc. ( NASDAQ: VBIV ) (VBI or the Company), a biopharmac...
2023-07-06 08:32:06 ET Allarity Therapeutics ALLR -53% after pricing public offering to $11M ASLAN Pharmaceuticals Limited ( ASLN ) -33% to host webcast on July 6, 2023, to discuss phase 2b topline data from TREK-AD trial evaluating Eblasakimab in atopic dermatitis. ...
News, Short Squeeze, Breakout and More Instantly...
Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024 The partial response, which demonstrated a 67% reduction in tumor size vs. baseline, wa...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s ca...
PreHevbrio ® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 Initial encouraging tumor response data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) anno...